CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-10 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion · Stock Option (right to buy) | −333 | 2,667 | ||
| 2021-08-10 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion · Stock Option (right to buy) | −1,468 | 30,819 | ||
| 2021-07-19 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion | +333 | $5.17 | $2K | 333 |
| 2021-07-19 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion | +1,467 | $0.77 | $1K | 1,800 |
| 2021-07-19 | Echerd Margaret SVP, Principal Accntng Officer | Sale | −1,800 | $8.00 | $14K | 0 |
| 2021-07-19 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion · Stock Option (right to buy) | −333 | 3,000 | ||
| 2021-07-19 | Echerd Margaret SVP, Principal Accntng Officer | Exercise or conversion · Stock Option (right to buy) | −1,467 | 32,287 | ||
| 2021-06-18 | Finney Michael J. Director | Exercise or conversion | +9,000 | $0.68 | $6K | 461,572 |
| 2021-06-18 | Finney Michael J. Director | Exercise or conversion | +12,700 | $0.68 | $9K | 474,272 |
| 2021-06-18 | Finney Michael J. Director | Option exercise | +181,818 | $1.10 | $200K | 656,090 |
| 2021-06-18 | Finney Michael J. Director | Exercise or conversion · Stock Option (right to buy) | −9,000 | 0 | ||
| 2021-06-18 | Finney Michael J. Director | Exercise or conversion · Stock Option (right to buy) | −12,700 | 0 | ||
| 2021-06-18 | Finney Michael J. Director | Option exercise · Common Stock Purchase Warrant | −181,818 | 0 | ||
| 2021-06-16 | Wheadon David E. Director | Grant or award · Stock Option (right to buy) | +65,700 | 65,700 | ||
| 2021-06-16 | Yedid Robert A. Director | Grant or award · Stock Option (right to buy) | +15,097 | 15,097 | ||
| 2021-06-16 | WILSON KAREN J Director | Grant or award · Stock Option (right to buy) | +15,097 | 15,097 | ||
| 2021-06-16 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +15,097 | 15,097 | ||
| 2021-06-16 | Davis Todd C Director | Grant or award · Stock Option (right to buy) | +15,097 | 15,097 | ||
| 2021-06-16 | Echerd Margaret SVP, Principal Accntng Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-06-16 | Tucker Sean SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 |
Page 12 of 23 · 442 trades